Cardiologo Intervencionista, departamento de Hemodinamia hospital de cardiología UMAE 34, Monterrey NL, Mex. #UMAE34cathlab
Monterrey Nuevo León
Joined October 2013
- Tweets888
- Following538
- Followers851
- Likes942
Pinned Tweet
61 yo🧓, with NSTEMI, bcs of ostial DX lesion, besides chronic subexpanded stent in proximal LAD with severe 360° calcium.
Tx..
Dx => NC 3.0 POBA and DCB.
LAD => 3.5 shockwave and DCB.
What you think about DCB use in this double scenario ( 0-0-1 bif lesion NSTEMI/ISR-calcium)??
Dr. Eduardo Galvan retweeted
I am very pleased to share our latest publication as first author on management of coronary artery perforations in the Journal of American College of Cardiology(JACC).
Stepwise, case-based review from our UK centre.
🔗 jacc.org/doi/10.1016/j.jacca…
#JACC #cardiology #intervention
Dr. Eduardo Galvan retweeted
Mitral implantation of the Sapien M3 valve at HCU Valladolid.
One team, one direction: The patient.
Thank you to everyone who makes these milestones possible. Worth every sacrifice.
@sacyl @EdwardsLifesci @secardiologia @mariogago13 @AnestesiaHCUV
Hanging around on CRF CTO plus 2026 with friends.
@rickytiago @MauroEchavPinto @elpikos @mornei2011 Ulises Lopez, Francisco Díaz y Víctor Romero de BSCI – at Times Square, Manhattan
Dr. Eduardo Galvan retweeted
🗞️ Hot off the press: #STAR trial
First randomized controlled trial comparing two different technical strategies in #CTO #PCI
jacc.org/doi/10.1016/j.jacc.…
Dr. Eduardo Galvan retweeted
TAVI or TAVR? A timely #EHJVSHD viewpoint reviews the historical origins, guideline evolution, and semantic accuracy of transcatheter aortic valve therapy, arguing why TAVI best reflects the procedure performed👉🔗ow.ly/o78950XJrMZ
@EHJVSHDEiC @PanichellaG @IndolfiCiro @ESC_President @EAPCIPresident
Dr. Eduardo Galvan retweeted
.@WHO published a guideline in JAMA on the use and indications of #GLP-1 therapies for the management of #obesity in adults. The guideline offers two conditional recommendations to inform clinical practice and health policy.
Read the guideline: ja.ma/3MxvT40
Dr. Eduardo Galvan retweeted
Guidelines recommend dual antiplatelet therapy after CABG for acute coronary syndrome, but whether it reduces adverse events as compared with aspirin alone is unclear. Research findings from the TACSI trial are summarized in a new Quick Take video. nej.md/499wznZ
ALT A visual representation of the TACSI trial, which assessed whether dual antiplatelet therapy after CABG for acute coronary syndrome reduces adverse events as compared with aspirin alone.
Dr. Eduardo Galvan retweeted
A must-read paper in #EHJ!
Coronary revascularization: a long-term perspective.
A State-of-the-Art review forecasting advancements by 2040, drawing on historical trends and recent breakthroughs.
@escardio @ESC_Journals #CardioTwitter
academic.oup.com/eurheartj/a…
Dr. Eduardo Galvan retweeted
ACTUALIZACIÓN: CONTRADICCIONES ENTRE PLANTA Y CONCESIONARIO
Adquirí una Volkswagen Tiguan 2025 R-Line el 23 de julio 2025. Confié en la marca y en su seguridad. Hoy, después de 3 ingresos a garantía y casi 3 meses sin mi vehículo, sigo sin solución. @Volkswagen_MX @Profeco
Dr. Eduardo Galvan retweeted
Provocative study from the RENOVATE trialists and Samsung Med Cntr suggesting use of intravascular imaging may eliminate long-term diffs between CABG & PCI. Not definitive absent a powered RCT, but should be enough to mandate IVI in these pts, esp with class I guidelines. Agree?
Dr. Eduardo Galvan retweeted
Estrategia de reducción de stents frente a revascularización coronaria percutánea convencional en el IAMCEST: diseño del ensayo COPERNICAN #REC #Aheadofprint @sjorge4 @drassantos @EvaRumiz @AntonioGomezM21 @fer_iver @cardioyoguini @hect2701 @ignamatsant revespcardiol.org/es-estrate…
Dr. Eduardo Galvan retweeted
📢 NEW State-of-the-Art Review
Advanced coronary imaging techniques—IVUS, OCT, NIRS, and CCTA—enable detailed assessment of plaque morphology, vulnerability, and therapeutic response.
This comprehensive review by García-García et al. outlines current evidence and clinical implications.
Read here: ow.ly/gxYH50Wtaso
@hect2701 @sjorge4 @christosbouran1
#Cardiology #Atherosclerosis #CoronaryImaging
Knowledge, dinner, and friends, great night with @mmamas1973 an friends in #CITIC Mexico City. Hope you had have a safe come back home @mmamas1973
Dr. Eduardo Galvan retweeted
New in EuroIntervention🔥
SCAI/EAPCI/ACVC expert consensus on cardiogenic shock in women.
A comprehensive, evidence-based guide to diagnosis, monitoring, and treatment—across CS etiologies and clinical settings. #europcr #eapci #cardiogenicshock
ow.ly/fAn250VVpLr
Dr. Eduardo Galvan retweeted
Are pressure-based indices vessel agnostic? Pressure derived indices in the Left Main @achir76 @drkogallagher @DrOzanDemir @k_desilva @mattlkw @divaka_perera @ukHeartResearch @theBHF #cardiotwitter #AHAJournals ahajrnls.org/3H6YdY0
Dr. Eduardo Galvan retweeted
🔍🖊️ ¿Quiere escribir un artículo de revisión?
¡Aquí encontrará los mejores tips para organizar, analizar y comunicar su trabajo con claridad y precisión! 📚✨ ¡Que su revisión sea imprescindible! 🔬
🧩sciencedirect.com/science/ar…
Dr. Eduardo Galvan retweeted
🔥Just published🔥
"Catheter-based techniques for pulmonary embolism treatment" by @Costa_F_8, @MicariAntonio et al.
✅A detailed review on CDT & CDMT
✅Practical strategies for device selection, procedural planning & risk stratification
✅Insights from the PEERLESS trial
🔗 eurointervention.pcronline.c…
#InterventionalCardiology #PulmonaryEmbolism #CDMT #CDT #PEERLESS #Cardiology
Dr. Eduardo Galvan retweeted
This review provides a practical outlook on catheter-directed therapies for pulmonary embolism, outlining optimal procedural planning, device selection, technical execution, evaluation of results, and management of complications. eurointervention.pcronline.c…
